Effects of duration of diabetes on behavioral and cognitive parameters in streptozotocin-induced juvenile diabetic rats

Malaysian Journal of Medical Sciences

Volumn 18, Issue 4, 2011, Pages 25-30

  Rajashree, Ravishankar ^a   Kholkute, Sanjiva D ^b   Goudar, Shivaprasad S ^a  

^a JAWAHARLAL NEHRU MEDICAL COLLEGE   (India)

^b INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

Author keywords

Anxiety; Cognition; Juvenile onset diabetes mellitus; Learning; Maze learning; Memory; Rats

Indexed keywords

STREPTOZOCIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; BEHAVIOR DISORDER; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HYPERGLYCEMIA; JUVENILE DIABETES MELLITUS; MALE; MAZE TEST; NONHUMAN; ONSET AGE; PERINATAL PERIOD; RAT; STREPTOZOCIN DIABETES;

EID: 80053490661     PISSN: 1394195X     EISSN: 21804303     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Adeghate E, Schattner P, Dunn E. An update on the etiology and epidemiology of diabetes mellitus. Ann N Y Acad Sci. 2006; 1084:1-29.
2. Ramanathan M, Jaiswal AK, Bhattacharya SK. Differential effects of diazepam on anxiety in streptozotocin induced diabetic and non-diabetic rats. Psychopharmacology (Berl). 1998;135(4):361-367.
3. Kuhad A, Chopra K. Curcumin attenuate diabetic encephalopathy in rats: Behavioral and biochemical evidences. Eur J Pharmacol. 2007;576(1-3):34-42.
4. Alvarez EO, Beauquis J, Revsin Y, Banzan AM, Roig P, De Nicola AF, et al. Cognitive dysfunction and hippocampal changes in experimental type 1 diabetes. Behav Brain Res. 2009;198(1):224-230.
5. Brands AM, Biessels GJ, De Haan EH, Kappelle LJ, Kessels RP. The effects of type 1 diabetes on cognitive performance: A meta-analysis. Diabetes Care. 2005;28(3):726-735.
6. Ryan CM, Williams TM. Effects of insulin-dependent diabetes on learning and memory effciency in adults. J Clin Exp Neuropsychol. 1993;15(5):685-700.
7. Thorre K, Chaouloff F, Sarre S, Meeusen R, Ebinger G, Michotte Y. Differential effects of restraint stress on hippocampal 5-HT metabolism and extracellular levels of 5-HT in streptozotocin-diabetic rats. Brain Res. 1997;772(1-2):209-216.
8. Sima AA, Zhang W, Muzik O, Kreipke CW, Rafols JA, Hoffman WH. Sequential abnormalities in type 1 diabetic encephalopathy and the effects of C-Peptide. Rev Diabet Stud. 2009;6(3):211-222.
9. Toth C, Schmidt AM, Tuor UI, Francis G, Foniok T, Brussee V, et al. Diabetes, leukoencephalopathy and rage. Neurobiol Dis. 2006;23(2):445-461.
10. Schoenle EJ, Schoenle D, Molinari L, Largo RH. Impaired intellectual development in children with Type I diabetes: Association with HbA(1c), age at diagnosis and sex. Diabetologia. 2002;45(1): 108-114.
11. Kulkarni SK. Hand book of experimental pharmacology. 3rd ed. Delhi (IN): Vallabh Prakashan; 1999.
12. Meiri N, Chelardini C, Tesco G, Galeotti N, Dahl D, Tomsic D, et al. Reversible antisense inhibition of Shaker-like Kv1.1 potassium channel expression impairs associative memory in mouse and rat. Proc Natl Acad Sci U S A. 1997;94(9):4430-4434.
13. Walther T, Balschun D, Voigt JP, Fink H, Zuschratter W, Birchmeier C, et al. Sustained long term potentiation and anxiety in mice lacking the Mas protooncogene. J Biol Chem. 1998;273(19): 11867-11873.
14. Carrie I, Clement M, de Javel D, Frances H, Bourre JM. Phospholipid supplementation reverses behavioral and biochemical alterations induced by n-3 polyunsaturated fatty acid defciency in mice. J Lipid Res. 2000;41(3):473-480.
15. Bures J, Buresova O, Huston JP. Techniques and basic experiments for the study of brain and behavior. 2nd ed. Amsterdam (NL): Elsevier Science; 1983.
16. Nayak V, Patil PA. Antidepressant activity of fosinopril, ramipril and losartan but not of lisinopril in depressive paradigms of albino rats and mice. Indian J Exp Biol. 2008;46(3):180-184.
17. Pellow S, Chopin P, File SE, Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods. 1985;14(3):149-167.
18. Hofteizer B, Carpenter AM. Comparison of streptozotocin and alloxan-induced diabetes in rats, including volumetric quantization of pancreatic islet cells. Diabetologia. 1973;9(3):178-184.
19. Rodgers RJ, Dalvi A. Anxiety, defence and the elevated plus-maze. Neurosci Biobehav R. 1997;21(6): 801-810.
20. Cavalli J, Bertoglio LJ, Carobrez AP. Pentylenetetrazole as an unconditioned stimulus for olfactory and contextual fear conditioning in rats. Neurobiol Learn Mem. 2009;92(4):512-518.
21. Hansen SL, Sperling BB, Sanchez C. Anticonvulsant and antiepileptogenic effects of GABA receptor ligands in pentylenetetrazole-kindled mice. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(1):105-113.
22. De Carvalho RS, Duarte FS, de Lima TC. Involvement of GABAergic non-benzodiazepine sites in the anxiolytic-like and sedative effects of the favonoid baicalein in mice. Behav Brain Res. 2011;221(1): 75-82.
23. Lister RG. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl). 1987;92(2):180-185.
24. Setem J, Pinheiro AP, Motta VA, Morato S, Cruz AP. Ethopharmacological analysis of 5-HT ligands on the rat elevated plus-maze. Pharmacol Biochem Behav. 1999;62(3):515-521.
25. Schaefer ML, Wong ST, Wozniak DF, Muglia LM, Liauw JA, Zhuo M, et al. Altered stress-induced anxiety in adenylyl cyclase type VIII-defcient mice. J Neurosci. 2000;20(13):4809-4820.
26. Fegley DB, Holmes A, Riordan T, Faber CA, Weiss JR, Ma S, et al. Increased fear- and stress-related anxietylike behavior in mice lacking tuberoinfundibular peptide of 39 residues. Genes Brain Behav. 2008;7(8):933-942.
27. Holmes CS, Hayford JT, Gonzalez JL, Weydert JA. A survey of cognitive functioning at difference glucose levels in diabetic persons. Diabetes Care. 1983;6(2):180-185.
28. Kim B, Backus C, Oh S, Hayes JM, Feldman EL. Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. Endocrinology. 2009;150(12):5294-5301.
29. Heikkila O, Lundbom N, Timonen M, Groop PH, Heikkinen S, Makimattila S. Hyperglycaemia is associated with changes in the regional concentrations of glucose and myo-inositol within the brain. Diabetologia. 2009;52(3):534-540.
30. Ho MS, Weller NJ, Ives FJ, Carne CL, Murray K, Vanden Driesen RI, et al. Prevalence of structural central nervous system abnormalities in early-onset type 1 diabetes mellitus. J Pediatr. 2008;153(3):385-390.
31. Van Duinkerkeu E, Klein M, Schoonenboom NS, Hoogma RP, Moll AC, Snoek FJ, et al. Functional brain connectivity and neurocognitive functioning in patients with longstanding type 1 diabetes with and without microvascular complications: A magnetoencephalography study. Diabetes. 2009;58(10):2335-2343.
32. Kamal A, Biessels GJ, Gispen WH, Ramakers GM. Synaptic transmission changes in the pyramidal cells of the hippocampus in streptozotocin-induced diabetes mellitus in rats. Brain Res. 2006;1073- 1074:276-80.
33. Sima AA, Kamiya H, Li ZG. Insulin, C-peptide, hyperglycemia, and central nervous system complications in diabetes. Eur J Pharmacol. 2004;490(1-3):187-197.
34. Biessels GJ, Deary TJ, Ryan CM. Cognition and diabetes: A lifespan perspective. Lancet Neurol. 2008;7(2):184-190.
35. Biessels GJ. Diabetic encephalopathy. In: Veves A, Malik RA, editors. Diabetic neuropathy: Clinical management. 2nd ed. Totowa (NJ): Humana Press Inc.; 2007. p. 187-205.